

Press Release dated 04<sup>TH</sup> January, 2024

## Accent Microcell Limited announces first results post listing for H1FY2024 (unaudited)

Ahmedabad, India | January 04, 2024: Accent Microcell Limited (NSE EMERGE: ACCENTMIC), a leading global excipients-based pharmaceuticals company, today announced its unaudited results for the Half Year (H1) ended as at 30<sup>th</sup> September 2023.

### Financial Highlights

#### EBITDA in INR and in %

Sr. No.	Particulars	(Amount in Lacs)	
		FY 2023-2024 H1 (unaudited)	FY 2022-2023 (Audited)
1	PAT	1410.16	1223.21
	Add:-		
2	Interest	73.76	213.01
3	Tax	317.86	256.67
4	Depreciation & Amortisation	212.81	410.83
5	<b>EBITDA (1+2+3+4)</b>	<b>2014.59</b>	<b>2103.72</b>
6	Revenue from operations	10929.99	20290.41
7	<b>EBITDA %</b>	<b>18.43</b>	<b>10.37</b>
8	<b>PAT %</b>	<b>12.90</b>	<b>6.03</b>


#### ROE and ROCE in %

Sr. No.	Particulars	(Amount in Lacs)			
		FY 2023-2024 H1(unaudited)	FY 2022-2023 (Audited)	FY 2021-2022 (Audited)	FY 2020-2021 (Audited)
1	Return on Equity (ROE)				
a.	PAT	1410.16	1223.21	821.57	620.62
b.	Shareholder's fund	7599.62	5042.77	3806.47	3087.94
1	<b>Return on Equity %</b>	<b>18.56</b>	<b>24.26</b>	<b>21.58</b>	<b>20.10</b>
2	Return on Capital employed (ROCE)				
a.	EBIT (PAT+Finance Cost+Tax)	1812.77	1751.63	1284.93	1095.68
b.	Capital Employed	8297.65	7309.86	6207.12	6140.29
2	<b>ROCE %</b>	<b>21.85</b>	<b>23.96</b>	<b>20.70</b>	<b>17.84</b>

Note:-

1. ROE and ROCE for H1FY24 (unaudited) is not annualised

YOY ON ROE AND ROCE COMPARISON H1FY24 (NOT ANNUALISED AND UNAUDITED) in %



### Key Highlights for H1 FY2024

- Accent completed successful listing on NSE Emerge on 15<sup>th</sup> December 2023
- Money raised will be used to increase capacity via Company's new proposed plant -3 at Nayka Taluka: - Kheda
- Accent declares its maiden results for H-1 viz., September 30, 2023 after listing.
- PAT for H-1 '24 crosses PAT for full year of 2022-23
- EBITDA Margins of **H1FY24 at 18.43%** compared to **10.37 % margins** for full year of FY23
- Margin expansion led by lower input cost and lower freight rates.
- Both plants continue to operate at its peak vis-à-vis book order position.
- Speaking on the results, the promoters of accent comments that we are very happy to share the robust set of numbers with new shareholders.
- Presently working on trial order received from Global Leader in Pharma and Chemical industry.
- Accent's products, thanks to all the hardwork we have put in over the years, are now widely recognized across global markets. We are seeing huge demand which is leading us to operate at optimum utilization capacity.
- While our new plant with increased capacity will become fully operational by mid-2025.
- We are continuously working to expand our product mix to deliver higher revenue and higher margins for FY 2024-25.
- As of now Accent is a net debt free company and promoter envisages it to be on a similar way.

We hope to continue our momentum in H2FY24 and end the financial year with a robust performance.